Comprehensive Overview of Steroids: Mechanisms, Uses, and Side Effects
Steroids fall into two distinct categories—corticosteroids (glucocorticoids) and anabolic-androgenic steroids (AAS)—each with fundamentally different mechanisms, clinical applications, and risk profiles that require separate consideration.
Corticosteroids (Glucocorticoids)
Mechanism of Action
Glucocorticoids work by binding to cytosolic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression 1. They primarily:
- Suppress inflammatory genes (cytokines, adhesion molecules, inflammatory enzymes) through interaction with pro-inflammatory transcription factors like NF-κB and AP-1
- Induce anti-inflammatory genes including lipocortin-1, IL-1 receptor antagonist, and secretary leukocyte proteinase inhibitor
- Suppress the hypothalamic-pituitary-adrenal (HPA) axis by inhibiting CRH and ACTH production, leading to adrenal cortex atrophy with prolonged use 2
Clinical Uses
Glucocorticoids serve as cornerstone therapy for 2:
- Autoimmune diseases
- Inflammatory disorders
- Severe allergic reactions
- Transplant rejection prevention
- Hematologic malignancies
They are administered via multiple routes: oral, inhaled, intranasal, intra-articular, topical, and intravenous.
Side Effects and Complications
Even low-dose, long-term therapy (prednisone 2.5-7.5 mg/day) carries significant risks 2:
Cardiovascular:
- Hypertension
- Increased thrombotic risk (venous thromboembolism and arterial events) 3
- Cardiovascular disease
Metabolic:
- Diabetes mellitus
- Dyslipidemia
Musculoskeletal:
- Osteoporosis and fractures
- Muscle degeneration with long-term use 4
Endocrine:
- Glucocorticoid-induced adrenal insufficiency—an inevitable consequence of chronic therapy requiring careful monitoring 2
- Risk of adrenal crisis during stress, illness, or abrupt discontinuation
Other:
- Severe infections
- Gastrointestinal complications
- Increased overall mortality
Critical pitfall: Patients on chronic glucocorticoids presenting with hemodynamic instability, vomiting, or diarrhea should be presumed to have adrenal crisis and treated immediately with parenteral glucocorticoids and fluid resuscitation, regardless of dose or route of administration 2.
Anabolic-Androgenic Steroids (AAS)
Mechanism of Action
AAS are synthetic testosterone derivatives that 5, 6:
- Bind to androgen receptors in target tissues after intramuscular injection or oral ingestion
- Biotransform into various metabolites within cells
- Promote protein synthesis and nitrogen retention in lean body mass
- Increase muscle size and strength at supraphysiologic doses (therapeutic doses in eugonadal men show minimal anabolic effects)
Clinical Uses
Legitimate medical applications 7:
- Testosterone replacement therapy for hypogonadism:
- Primary hypogonadism (Klinefelter syndrome, cryptorchidism, testicular trauma/torsion, chemotherapy/radiation effects)
- Secondary hypogonadism (hyperprolactinemia, severe obesity, opioid/glucocorticoid use, pituitary tumors)
- Combined primary and secondary hypogonadism
Benefits in hypogonadal men include:
- Small improvements in libido, erectile function, sexual activity, and satisfaction
- Improvements in bone mineral density and bone strength
- No significant improvements in energy, mood, or cognition 7
Side Effects and Complications
AAS abuse at supraphysiologic doses causes severe, multi-system toxicity 5, 8, 9:
Cardiovascular (most concerning):
- Systolic BP increase by 12.43 mmHg and diastolic BP by 8.09 mmHg 8
- Venous thromboembolism and arterial thromboses driven by polycythemia, platelet hyper-aggregability, and vascular injury 3
- Atherosclerosis progression, myocardial infarction, stroke, and death 9
- Cardiomyopathy 5
- Erythrocytosis (hematocrit >54%) 7
Hepatic:
- AST elevation by 14.47 U/L and ALT by 12.16 U/L indicating significant liver stress 8
- Hepatotoxicity 5
Endocrine:
- Profound testosterone suppression (reduction of 141.57 ng/dL) 8
- Post-use hypogonadism from HPA axis dysregulation, often long-term and driving continued use despite harms 10
- Testosterone deficiency, erectile dysfunction 5
- Gynecomastia 5
Metabolic:
- LDL-C increase by 9.12 mg/dL 8
- Low HDL-C, high triglycerides, impaired fasting glucose (metabolic syndrome) 9
- Dyslipidemia 5
Renal:
- Proteinuria and structural kidney damage 9
Dermatologic:
- Acne vulgaris 5
Psychiatric:
- Body/muscle dysmorphia
- AAS use disorder—an emerging addiction with tolerance development driven by hormonal dysregulation 10
Musculoskeletal:
- Paradoxically, while short-term use may aid muscle contusion healing, evidence is limited to animal models 4
Management of AAS-Related Complications
For thrombotic events:
- Standard anticoagulation with low-molecular-weight heparin or direct oral anticoagulants preferred to avoid warfarin-steroid interactions 3
- Re-evaluate ongoing steroid necessity
- Close bleeding monitoring
For AAS use disorder:
- Multidisciplinary team including psychiatry, addiction medicine, and endocrinology 10
- Screen and treat body dysmorphia
- Manage post-use hypogonadism
- Harm-reduction strategies
Key Clinical Distinctions
Corticosteroids are legitimate anti-inflammatory/immunosuppressive medications with unavoidable HPA suppression requiring vigilance for adrenal insufficiency. Even low doses carry cardiovascular, metabolic, and bone risks.
Anabolic-androgenic steroids have narrow legitimate use (hypogonadism treatment) but are widely abused at supraphysiologic doses, causing severe cardiovascular, hepatic, endocrine, and renal toxicity, plus addiction potential. Oxidative stress and inflammation drive multi-organ damage regardless of dose or duration 9.